Toward liquid biopsies in cancer treatment: application of circulating tumor DNA

Lise Barlebo Ahlborn, Olga Østrup

Abstract

Circulating tumor DNA (ctDNA) refers to the fraction of cell-free DNA in a patient's blood originating from tumor cells. Increased knowledge about tumor genomics, improvements in targeted therapies, and accompanying advances in DNA-sequencing technologies have increased the interest in using ctDNA as a minimally invasive tool in cancer diagnostics and treatment. Especially, early tumor detection including identification of minimal residual disease and stratification of adjuvant therapy are promising approaches. Also, ctDNA showed to be reliable in treatment monitoring and can be used to assess therapy resistance due to the broad variety of tumor subclones captured in ctDNA. Therefore, using ctDNA in the clinical setting has the potential to improve therapeutic outcomes. In the present review, we summarize the status of ctDNA in oncology with focus of being an alternative to tissue biopsies in early detection and treatment monitoring.

OriginalsprogEngelsk
TidsskriftAPMIS - Journal of Pathology, Microbiology and Immunology
Vol/bind127
Udgave nummer5
Sider (fra-til)329-336
Antal sider8
ISSN0903-4641
DOI
StatusUdgivet - maj 2019

Fingeraftryk

Dyk ned i forskningsemnerne om 'Toward liquid biopsies in cancer treatment: application of circulating tumor DNA'. Sammen danner de et unikt fingeraftryk.

Citationsformater